Abivax shares soar 23% as media report reignites M&A chatter

Core Viewpoint - Shares in Abivax increased by 23%, surpassing 121 euros, following reports of Eli Lilly's continued interest in acquiring the French biotech company [1] Company Summary - Abivax's stock performance reflects a significant rise, indicating positive market sentiment regarding potential acquisition talks with Eli Lilly [1] - Eli Lilly, a major player in the pharmaceutical industry, is showing interest in expanding its portfolio through the acquisition of Abivax, which may enhance its capabilities in the biotech sector [1]